| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $13.0M | +68.2% |
| SG&A Expense | $3.1M | +87.8% |
| Operating Income | -$16.0M | -71.7% |
| Net Income | -$15.8M | -77.6% |
| EPS (Basic) | -$1.21 | -75.4% |
| EPS (Diluted) | -$1.21 | -75.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $4.1M | -41.5% |
| Total Assets | $4.1M | -41.5% |
| Current Liabilities | $1.6M | +429.8% |
| Total Liabilities | $1.6M | +429.8% |
| Stockholders' Equity | $2.5M | -62.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$7.3M | -12.2% |
| Financing Cash Flow | $4.4M | — |